Reports Q2 revenue $4.45M, consensus $4.36M. “During the second quarter, we made steady progress executing on our strategic objectives,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra. “We are encouraged by favorable vote from the FDA’s Genetic Metabolic Diseases Advisory Committee, that data presented support that arimoclomol is effective in the treatment in patients with Niemann Pick disease type C. While the vote is non-binding, we believe it is an important factor as the FDA completes its consideration for approval. Additionally, we continue the launch of OLPRUVA with a keen focus on driving patient awareness and intend to use the same commercial team to launch arimoclomol, if approved. Additionally, we expect to meet with the FDA to discuss the design of a pivotal Phase 3 trial to study KP1077 in idiopathic hypersomnia at the end of third quarter.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- ZVRA Earnings this Week: How Will it Perform?
- Zevra Therapeutics 9.2M share Spot Secondary priced at $6.50
- Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
- Zevra Therapeutics announces common stock offering, no amount given
- Zevra Therapeutics Announces Proposed Public Offering of Common Stock